MicroRNA miR-215-5p Regulates Doxorubicin-induced Cardiomyocyte Injury by Targeting ZEB2

Area of Science:

• Cardiology
• Molecular Biology
• Oncology

Background:

• Doxorubicin (DOX) is a vital chemotherapy drug, but its use is limited by cardiotoxicity.
• MicroRNAs play a key role in mediating heart cell injury.
• Understanding microRNA involvement is crucial for mitigating DOX side effects.

Purpose of the Study:

• To investigate the role of miR-215-5p in Doxorubicin-induced mouse HL-1 cardiomyocyte injury.
• To explore the potential of targeting miR-215-5p for therapeutic benefit.

Main Methods:

• Established an in vitro model of DOX-induced cardiotoxicity using HL-1 cells.
• Quantified gene expression via RT-qPCR, cell viability with CCK-8, and cell death/apoptosis using TUNEL, flow cytometry, and caspase assays.
• Identified miR-215-5p targets using luciferase reporter assays.

Main Results:

• DOX treatment induced cardiomyocyte injury and upregulated miR-215-5p in HL-1 cells.
• Inhibiting miR-215-5p reduced DOX-induced cell death and apoptosis.
• ZEB2 was identified as a direct target of miR-215-5p, with its expression decreased by DOX and restored by miR-215-5p inhibition.

Conclusions:

• miR-215-5p inhibition protects HL-1 cells from DOX-induced injury.
• This protection is mediated through the upregulation of its target gene, ZEB2.
• Targeting miR-215-5p presents a promising strategy to combat DOX cardiotoxicity.